“We will continue to explore the potential of CEACAM5 as a biomarker in cancer ... cancer therapy Sarclisa (isatuximab) and phase 2 anti-ICOS antibody alomfilimab for solid tumours.

an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist ...